ECSP22083904A - Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso - Google Patents

Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Info

Publication number
ECSP22083904A
ECSP22083904A ECSENADI202283904A ECDI202283904A ECSP22083904A EC SP22083904 A ECSP22083904 A EC SP22083904A EC SENADI202283904 A ECSENADI202283904 A EC SENADI202283904A EC DI202283904 A ECDI202283904 A EC DI202283904A EC SP22083904 A ECSP22083904 A EC SP22083904A
Authority
EC
Ecuador
Prior art keywords
compounds
preparation
methods
pharmaceutical compositions
pharmaceutically acceptable
Prior art date
Application number
ECSENADI202283904A
Other languages
English (en)
Inventor
Bingcan Liu
Patrick Beaulieu
Alexander Perryman
Janek Szychowski
Frédéric Vallée
Robert Papp
Jean-François Truchon
Evelyne Dietrich
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of ECSP22083904A publication Critical patent/ECSP22083904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en el presente documento pueden ser inhibidores de la cinasa inhibidora de cdc2 específica de treonina y tirosina (Myt1). También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
ECSENADI202283904A 2020-04-01 2022-10-27 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso ECSP22083904A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063003745P 2020-04-01 2020-04-01

Publications (1)

Publication Number Publication Date
ECSP22083904A true ECSP22083904A (es) 2022-11-30

Family

ID=77927736

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202283904A ECSP22083904A (es) 2020-04-01 2022-10-27 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Country Status (14)

Country Link
US (1) US20230151014A1 (es)
EP (1) EP4126879B1 (es)
JP (2) JP7714570B2 (es)
KR (1) KR20230011279A (es)
CN (1) CN115916783A (es)
AU (1) AU2021250744A1 (es)
BR (1) BR112022019611A2 (es)
CA (1) CA3177200A1 (es)
CO (1) CO2022015638A2 (es)
CR (1) CR20220558A (es)
EC (1) ECSP22083904A (es)
IL (1) IL296934B1 (es)
MX (1) MX2022012178A (es)
WO (1) WO2021195781A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173955A1 (en) * 2020-04-01 2021-10-07 Repare Therapeutics Inc. Methods of using myt1 inhibitors
KR20230107801A (ko) * 2020-09-30 2023-07-18 에프엘2022-001, 인코포레이티드 Hsd17b13 억제제 및 이의 용도
CA3214900A1 (en) * 2021-04-07 2022-10-13 Jimmy FOURTOUNIS Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer
US12435090B2 (en) 2021-10-04 2025-10-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
EP4479403A4 (en) * 2022-02-18 2026-02-11 Insilico Medicine Ip Ltd MEMBRANE-ASSOCIATED TYROSINE AND THREONIN-SPECIFIC CDC2 KINASE INHIBITORS (PKMYT1) AND THEIR USES
WO2023155892A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
US20250197405A1 (en) * 2022-03-15 2025-06-19 Insilico Medicine Ip Limited Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
CN119156388A (zh) * 2022-04-15 2024-12-17 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
WO2023220831A1 (en) * 2022-05-18 2023-11-23 Repare Therapeutics Inc. Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
US20250388583A1 (en) * 2022-06-23 2025-12-25 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
JP2025523030A (ja) 2022-07-12 2025-07-17 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｍｙｔ１阻害剤としての化合物
WO2024041440A1 (en) * 2022-08-24 2024-02-29 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
EP4582102A1 (en) 2022-08-31 2025-07-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent and therapeutic method which are for cancer patients exhibiting rb1 functional deterioration and which involve concomitant use of myt1 inhibitor and chemotherapeutic agent
WO2024061343A1 (zh) * 2022-09-23 2024-03-28 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
EP4624471A4 (en) * 2022-11-25 2026-03-18 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd PKMYT1 INHIBITOR, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND ITS USE
EP4638449A1 (en) * 2022-12-22 2025-10-29 Repare Therapeutics Inc. Methods of making 2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6- dimethyl-1h-pyrrolo-[2,3-b]pyridine-3-carboxamide, a myt1 inhibitor
WO2024153249A1 (zh) * 2023-01-20 2024-07-25 杭州英创医药科技有限公司 作为pkmyt1抑制剂的化合物
WO2024166131A1 (en) 2023-02-09 2024-08-15 Satyarx Pharma Innovations Private Limited Heteroaryl compounds as pkmyt1 inhibitors
EP4673436A1 (en) * 2023-02-28 2026-01-07 F. Hoffmann-La Roche AG Indazole compounds as pkmyt1 kinase inhibitors
WO2024218235A1 (en) 2023-04-19 2024-10-24 Sanofi Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof
WO2024222899A1 (zh) * 2023-04-28 2024-10-31 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
CN121057733A (zh) 2023-04-28 2025-12-02 赛诺菲 吡啶并咪唑酮化合物、其制备及其治疗用途
WO2024252276A1 (en) * 2023-06-05 2024-12-12 Astrazeneca Ab Pyrrolopyrimidine carboxamides
CN121358735A (zh) * 2023-07-04 2026-01-16 杭州领业医药科技有限公司 Rp-6306的晶型及其制备方法和用途
CN121335901A (zh) * 2023-07-06 2026-01-13 四川科伦博泰生物医药股份有限公司 杂芳环化合物、药物组合物及其制备方法和用途
WO2025040014A1 (zh) * 2023-08-18 2025-02-27 英矽智能科技知识产权有限公司 并环化合物及其制备方法和用途
CN121712774A (zh) * 2023-08-23 2026-03-20 英矽智能科技知识产权有限公司 靶向pkmyt1的双官能化合物和使用方法
AR133820A1 (es) 2023-09-14 2025-11-05 Debiopharm Int Sa Combinación de un inhibidor de wee1 y un inhibidor de pkmyt1
WO2025066504A1 (en) * 2023-09-28 2025-04-03 Laekna Therapeutics Shanghai Co., Ltd. Bicyclic heteroaromatic compounds and their use as pkmyt1 inhibitors
WO2025074271A1 (en) * 2023-10-02 2025-04-10 Repare Therapeutics Inc. Myt1 inhibitors for the treatment of cancers harboring replication stress mutations
WO2025092773A1 (zh) * 2023-10-31 2025-05-08 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025119300A1 (zh) * 2023-12-08 2025-06-12 广东东阳光药业股份有限公司 Myt1激酶抑制剂化合物、其药物组合物及其用途
WO2025140592A1 (zh) * 2023-12-29 2025-07-03 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其制备方法和医药用途
KR20250112480A (ko) 2024-01-17 2025-07-24 성균관대학교산학협력단 회전 장애 이성질체를 포함하는 신규한 n-/2-/3-아릴인돌 유도체 화합물 및 이의 제조 방법
CN120365270A (zh) * 2024-01-23 2025-07-25 杭州中美华东制药有限公司 具有pkmyt1抑制作用的化合物
WO2025169150A1 (en) * 2024-02-09 2025-08-14 Repare Therapeutics Inc. Crystalline forms, crystalline salt forms, compositions containing the same, and methods of using the same
WO2025195505A1 (zh) * 2024-03-22 2025-09-25 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂化合物及其应用
WO2025242167A1 (zh) * 2024-05-23 2025-11-27 齐鲁制药有限公司 Pkmyt1抑制剂的多晶型、其制备方法及其应用
WO2026017827A1 (en) * 2024-07-18 2026-01-22 Astrazeneca Ab Carboxamide compounds as pkmyt1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531504A (ja) 1998-12-07 2002-09-24 スミスクライン・ビーチャム・コーポレイション Ｍｙｔ１キナーゼ阻害剤
CO5261594A1 (es) 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9856259B2 (en) * 2014-09-15 2018-01-02 Plexxikon Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
MX2022012178A (es) 2022-12-08
CA3177200A1 (en) 2021-10-07
KR20230011279A (ko) 2023-01-20
CO2022015638A2 (es) 2022-11-18
IL296934B1 (en) 2026-01-01
BR112022019611A2 (pt) 2022-11-29
EP4126879A1 (en) 2023-02-08
EP4126879B1 (en) 2026-01-21
WO2021195781A1 (en) 2021-10-07
JP2023521633A (ja) 2023-05-25
EP4126879A4 (en) 2024-04-10
JP7714570B2 (ja) 2025-07-29
CR20220558A (es) 2022-12-12
AU2021250744A1 (en) 2022-11-17
IL296934A (en) 2022-12-01
US20230151014A1 (en) 2023-05-18
CN115916783A (zh) 2023-04-04
JP2025142057A (ja) 2025-09-29

Similar Documents

Publication Publication Date Title
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
BR112022007612A2 (pt) Inibidores de raf quinases
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CL2023000655A1 (es) Degradadores de helios basados en pequeñas moléculas de piperidinilo; y uso
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2017009643A (es) Composiciones y métodos de uso de inhibidores de tirosina quinasa.
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2025014135A (es) Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos
CO2024009144A2 (es) Inhibidores de cinasa met
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
MX2023015436A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2024007240A (es) Moduladores de proteina quinasa asociada a rho (rock).
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos
CL2023000926A1 (es) Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma